Hammond, Terese C.
Purbhoo, Marco A.
Kadel, Sapana
Ritz, Jerome http://orcid.org/0000-0001-5526-4669
Nikiforow, Sarah
Daley, Heather
Shaw, Kit
van Besien, Koen
Gomez-Arteaga, Alexandra
Stevens, Don
Ortuzar, Waldo
Michelet, Xavier
Smith, Rachel
Moskowitz, Darrian
Masakayan, Reed
Yigit, Burcu
Boi, Shannon http://orcid.org/0000-0001-9479-5665
Soh, Kah Teong http://orcid.org/0000-0002-0146-0485
Chamberland, John
Song, Xin
Qin, Yu
Mishchenko, Ilya
Kirby, Maurice
Nasonenko, Valeriia
Buffa, Alexa http://orcid.org/0009-0007-4982-7788
Buell, Jennifer S.
Chand, Dhan
van Dijk, Marc http://orcid.org/0000-0002-0190-7814
Stebbing, Justin http://orcid.org/0000-0002-1117-6947
Exley, Mark A. http://orcid.org/0000-0002-5088-1032
Funding for this research was provided by:
Agenus Inc
Article History
Received: 28 March 2023
Accepted: 9 January 2024
First Online: 6 February 2024
Competing interests
: M.A.P., S.K., D.M., B.Y., S.B., X.M., R.M., A.B., J.S.B., and M.v.D. are current or former employees of MiNK Therapeutics and have received stock and compensation. M.K., A.B., D.C., V.N., W.O., K.S., X.S., J.C., Y.Q. are current employees of Agenus Inc and have received stock and compensation. J.S. from 2020 has been the Editor-in-Chief of Oncogene has sat on SABs for Vaccitech, Heat Biologics, Eli Lilly, Alveo Technologies, Pear Bio, Agenus (and received compensation), Equilibre Biopharmaceuticals, Graviton Bioscience Corporation, Celltrion, Volvox, Certis, Greenmantle, vTv Therapeutics, APIM Therapeutics, Onconox, IO Labs, Bryologyx, Zephyr AI and Benevolent AI. He has consulted with Lansdowne partners and Vitruvian. He chairs the Board of Directors for Xerion and previously BB Biotech Healthcare Trust PLC. M.A.E. is former employee and current consultant for MiNK, employed by Imvax Inc., I.M. has received consulting fees from Agenus and TCH is on MiNK Therapeutics SAB and a consultant, has received Agenus research funding and consulting fees, and is on the Pfizer International Viral Advisory Council. J.R. received research funding from Equillium, Kite Pharma, Novartis and Oncternal and served on SABs for Akron Biotech, Avrobio, Clade Therapeutics, Erbi Biosystems, Garuda Therapeutics, LifeVault Bio, Novartis, Smart Immune, Talaris Therapeutics and TScan Therapeutics. A.G.A. is on the SAB for Legend Biotech, and a speaker for Bristol Myers Squibb. S.N. sits on the SABs for Kite/Gilead, Iovance, GlaxoSmithKline, Sobi, A2 Bio. K.v.B. has received stock and other ownership from Hemogeny, has a consultant role to HemOgenyx, Glycostem, Gamida Cell, CTI, Intellia, SNIPR BIOME, MorphoSys, Incyte, Autolus, ADC Therapeutics, has received research funding from Precision Biosciences, Orca Bio, Bristol-Myers Squibb/Celgene, Calibr and Actinium Pharmaceuticals. No other author declares a conflict.